Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study.

Balk LJ, Coric D, Knier B, Zimmermann HG, Behbehani R, Alroughani R, Martinez-Lapiscina EH, Brandt AU, Sánchez-Dalmau B, Vidal-Jordana A, Albrecht P, Koska V, Havla J, Pisa M, Nolan RC, Leocani L, Paul F, Aktas O, Montalban X, Balcer LJ, Villoslada P, Outteryck O, Korn T, Petzold A; IMSVISUAL consortium.

Mult Scler J Exp Transl Clin. 2019 Sep 5;5(3):2055217319871582. doi: 10.1177/2055217319871582. eCollection 2019 Jul-Sep.

2.

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

Dekker I, Sombekke MH, Balk LJ, Moraal B, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2019 Aug 2:1352458519864933. doi: 10.1177/1352458519864933. [Epub ahead of print]

PMID:
31373535
3.

Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis.

Coric D, Ometto G, Montesano G, Keane PA, Balk LJ, Uitdehaag BMJ, Petzold A, Crabb DP, Denniston AK.

Eur J Neurol. 2019 Jul 25. doi: 10.1111/ene.14048. [Epub ahead of print]

PMID:
31342606
4.

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.

Dekker I, Leurs CE, Hagens MHJ, van Kempen ZLE, Kleerekooper I, Lissenberg-Witte BI, Barkhof F, Uitdehaag BMJ, Balk LJ, Wattjes MP, Killestein J.

Mult Scler Relat Disord. 2019 Aug;33:82-87. doi: 10.1016/j.msard.2019.05.017. Epub 2019 May 28.

PMID:
31174043
5.

Saccadic fatigability in the oculomotor system.

Nij Bijvank JA, van Rijn LJ, Kamminga M, Tan HS, Uitdehaag BMJ, Petzold A, Balk LJ.

J Neurol Sci. 2019 Jul 15;402:167-174. doi: 10.1016/j.jns.2019.05.024. Epub 2019 May 23.

PMID:
31154074
6.

Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.

Nij Bijvank JA, van Rijn LJ, Balk LJ, Tan HS, Uitdehaag BMJ, Petzold A.

Neurology. 2019 May 14;92(20):e2299-e2308. doi: 10.1212/WNL.0000000000007499. Epub 2019 Apr 19.

7.

Quantification of Visual Fixation in Multiple Sclerosis.

Nij Bijvank JA, Petzold A, Coric D, Tan HS, Uitdehaag BMJ, Balk LJ, van Rijn LJ.

Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1372-1383. doi: 10.1167/iovs.18-26096. Erratum in: Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2571.

PMID:
30938772
8.

Predicting clinical progression in multiple sclerosis after 6 and 12 years.

Dekker I, Eijlers AJC, Popescu V, Balk LJ, Vrenken H, Wattjes MP, Uitdehaag BMJ, Killestein J, Geurts JJG, Barkhof F, Schoonheim MM.

Eur J Neurol. 2019 Jun;26(6):893-902. doi: 10.1111/ene.13904. Epub 2019 Feb 2.

9.

Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis.

Leurs CE, Lopes Pinheiro MA, Wierts L, den Hoedt S, Mulder MT, Eijlers AJC, Schoonheim MM, Balk LJ, Uitdehaag BMJ, Killestein J, de Vries HE.

Mult Scler Relat Disord. 2019 Feb;28:44-49. doi: 10.1016/j.msard.2018.11.024. Epub 2018 Nov 30.

PMID:
30553168
10.

The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis.

Balcer LJ, Balk LJ, Brandt AU, Calabresi PA, Martinez-Lapiscina EH, Nolan RC, Paul F, Petzold A, Saidha S.

J Neuroophthalmol. 2018 Dec;38(4):494-501. doi: 10.1097/WNO.0000000000000732.

PMID:
30418332
11.

The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis.

Coric D, Nij Bijvank JA, van Rijn LJ, Petzold A, Balk LJ.

Neurodegener Dis Manag. 2018 Oct;8(5):323-335. doi: 10.2217/nmt-2018-0011. Epub 2018 Sep 18. Review.

PMID:
30226111
12.

A standardized protocol for quantification of saccadic eye movements: DEMoNS.

Nij Bijvank JA, Petzold A, Balk LJ, Tan HS, Uitdehaag BMJ, Theodorou M, van Rijn LJ.

PLoS One. 2018 Jul 16;13(7):e0200695. doi: 10.1371/journal.pone.0200695. eCollection 2018.

13.

The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.

Nauta IM, Balk LJ, Sonder JM, Hulst HE, Uitdehaag BM, Fasotti L, de Jong BA.

Mult Scler. 2019 Oct;25(11):1543-1546. doi: 10.1177/1352458518777295. Epub 2018 May 18.

PMID:
29775164
14.

Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophy.

Coric D, Petzold A, Uitdehaag BMJ, Balk LJ.

J Neurol Sci. 2018 Apr 15;387:16-20. doi: 10.1016/j.jns.2018.01.020. Epub 2018 Feb 3.

PMID:
29571856
15.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
16.

Structure-function relationships in the visual system in multiple sclerosis: an MEG and OCT study.

Tewarie P, Balk LJ, Hillebrand A, Steenwijk MD, Uitdehaag BMJ, Stam CJ, Petzold A.

Ann Clin Transl Neurol. 2017 Jul 25;4(9):614-621. doi: 10.1002/acn3.415. eCollection 2017 Sep.

17.

Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis.

Coric D, Balk LJ, Uitdehaag BMJ, Petzold A.

Eur J Neurol. 2017 Dec;24(12):1479-1484. doi: 10.1111/ene.13443. Epub 2017 Oct 9.

PMID:
28887838
18.

Ganglion cell layer measurements correlate with disease severity in patients with Alzheimer's disease.

den Haan J, Balk LJ, Verbraak FD.

Acta Ophthalmol. 2018 Mar;96(2):e265-e266. doi: 10.1111/aos.13550. Epub 2017 Aug 22. No abstract available.

19.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2018 Oct;24(11):1453-1460. doi: 10.1177/1352458517726381. Epub 2017 Aug 21.

20.

Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.

Balk LJ, Coric D, Nij Bijvank JA, Killestein J, Uitdehaag BM, Petzold A.

Mult Scler. 2018 May;24(6):767-776. doi: 10.1177/1352458517708463. Epub 2017 May 17.

21.

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.

Coric D, Balk LJ, Verrijp M, Eijlers A, Schoonheim MM, Killestein J, Uitdehaag BM, Petzold A.

Mult Scler. 2018 Feb;24(2):158-166. doi: 10.1177/1352458517694090. Epub 2017 Feb 1.

22.

A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer.

Nij Bijvank JA, Balk LJ, Tan HS, Uitdehaag BM, van Rijn LJ, Petzold A.

J Neurol. 2017 Mar;264(3):600-602. doi: 10.1007/s00415-017-8412-4. Epub 2017 Feb 13. No abstract available.

PMID:
28194531
23.

The APOSTEL recommendations for reporting quantitative optical coherence tomography studies.

Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, Schuman JS, Villoslada P, Calabresi P, Balcer L, Petzold A, Green AJ, Paul F, Brandt AU, Albrecht P; IMSVISUAL consortium.

Neurology. 2016 Jun 14;86(24):2303-9. doi: 10.1212/WNL.0000000000002774. Epub 2016 May 25.

24.

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.

Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, Killestein J, Uitdehaag BM, Petzold A, Green AJ.

J Neurol. 2016 Jul;263(7):1323-31. doi: 10.1007/s00415-016-8127-y. Epub 2016 May 3.

25.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
26.

Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant.

Steenwijk MD, Geurts JJ, Daams M, Tijms BM, Wink AM, Balk LJ, Tewarie PK, Uitdehaag BM, Barkhof F, Vrenken H, Pouwels PJ.

Brain. 2016 Jan;139(Pt 1):115-26. doi: 10.1093/brain/awv337. Epub 2015 Dec 4.

PMID:
26637488
27.

Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis.

Daams M, Steenwijk MD, Schoonheim MM, Wattjes MP, Balk LJ, Tewarie PK, Killestein J, Uitdehaag BM, Geurts JJ, Barkhof F.

Mult Scler. 2016 Apr;22(5):608-19. doi: 10.1177/1352458515596598. Epub 2015 Jul 24.

PMID:
26209593
28.

Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis.

Daams M, Steenwijk MD, Wattjes MP, Geurts JJ, Uitdehaag BM, Tewarie PK, Balk LJ, Pouwels PJ, Killestein J, Barkhof F.

Neurology. 2015 Jul 21;85(3):248-55. doi: 10.1212/WNL.0000000000001756. Epub 2015 Jun 26.

PMID:
26115736
29.

Visual pathway neurodegeneration winged by mitochondrial dysfunction.

Petzold A, Nijland PG, Balk LJ, Amorini AM, Lazzarino G, Wattjes MP, Gasperini C, van der Valk P, Tavazzi B, Lazzarino G, van Horssen J.

Ann Clin Transl Neurol. 2015 Feb;2(2):140-50. doi: 10.1002/acn3.157. Epub 2014 Dec 17.

30.

Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study.

Tewarie P, Schoonheim MM, Schouten DI, Polman CH, Balk LJ, Uitdehaag BM, Geurts JJ, Hillebrand A, Barkhof F, Stam CJ.

Hum Brain Mapp. 2015 Feb;36(2):603-18. doi: 10.1002/hbm.22650. Epub 2014 Oct 8.

PMID:
25293505
31.

Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis.

Sonder JM, Balk LJ, van der Linden FA, Bosma LV, Polman CH, Uitdehaag BM.

Mult Scler. 2015 Dec;21(14):1865-71. doi: 10.1177/1352458514544078. Epub 2014 Sep 25.

PMID:
25257617
32.

Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration.

Balk LJ, Petzold A, Oberwahrenbrock T, Brandt AU, Albrecht P.

Am J Ophthalmol. 2014 Oct;158(4):845. doi: 10.1016/j.ajo.2014.06.022. No abstract available.

PMID:
25220003
33.

Disruption of structural and functional networks in long-standing multiple sclerosis.

Tewarie P, Steenwijk MD, Tijms BM, Daams M, Balk LJ, Stam CJ, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F, Pouwels PJ, Vrenken H, Hillebrand A.

Hum Brain Mapp. 2014 Dec;35(12):5946-61. doi: 10.1002/hbm.22596. Epub 2014 Jul 22.

PMID:
25053254
34.

Physiological variation of retinal layer thickness is not caused by hydration: a randomised trial.

Balk LJ, Oberwahrenbrock T, Uitdehaag BM, Petzold A.

J Neurol Sci. 2014 Sep 15;344(1-2):88-93. doi: 10.1016/j.jns.2014.06.031. Epub 2014 Jun 30.

PMID:
25005893
35.

Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Balk LJ, Steenwijk MD, Tewarie P, Daams M, Killestein J, Wattjes MP, Vrenken H, Barkhof F, Polman CH, Uitdehaag BM, Petzold A.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):419-24. doi: 10.1136/jnnp-2014-308189. Epub 2014 Jun 27.

PMID:
24973342
36.

Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria.

Schippling S, Balk LJ, Costello F, Albrecht P, Balcer L, Calabresi PA, Frederiksen JL, Frohman E, Green AJ, Klistorner A, Outteryck O, Paul F, Plant GT, Traber G, Vermersch P, Villoslada P, Wolf S, Petzold A.

Mult Scler. 2015 Feb;21(2):163-70. doi: 10.1177/1352458514538110. Epub 2014 Jun 16.

PMID:
24948688
37.

Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis.

Balk LJ, Petzold A.

Neurodegener Dis Manag. 2014;4(2):165-76. doi: 10.2217/nmt.14.10. Review.

PMID:
24832034
38.

Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability.

Daams M, Weiler F, Steenwijk MD, Hahn HK, Geurts JJ, Vrenken H, van Schijndel RA, Balk LJ, Tewarie PK, Tillema JM, Killestein J, Uitdehaag BM, Barkhof F.

Mult Scler. 2014 Dec;20(14):1860-5. doi: 10.1177/1352458514533399. Epub 2014 May 8.

PMID:
24812042
39.

What explains gray matter atrophy in long-standing multiple sclerosis?

Steenwijk MD, Daams M, Pouwels PJ, Balk LJ, Tewarie PK, Killestein J, Uitdehaag BM, Geurts JJ, Barkhof F, Vrenken H.

Radiology. 2014 Sep;272(3):832-42. doi: 10.1148/radiol.14132708. Epub 2014 Apr 23. Erratum in: Radiology. 2014 Nov;273(2):629.

PMID:
24761837
40.

Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales.

Sonder JM, Balk LJ, Bosma LV, Polman CH, Uitdehaag BM.

Mult Scler. 2014 Oct;20(12):1616-23. doi: 10.1177/1352458514529173. Epub 2014 Apr 7.

PMID:
24710798
41.

A dam for retrograde axonal degeneration in multiple sclerosis?

Balk LJ, Twisk JW, Steenwijk MD, Daams M, Tewarie P, Killestein J, Uitdehaag BM, Polman CH, Petzold A.

J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):782-9. doi: 10.1136/jnnp-2013-306902. Epub 2014 Jan 28.

PMID:
24474822
42.

Disease course heterogeneity and OCT in multiple sclerosis.

Balk LJ, Tewarie P, Killestein J, Polman CH, Uitdehaag B, Petzold A.

Mult Scler. 2014 Aug;20(9):1198-206. doi: 10.1177/1352458513518626. Epub 2014 Jan 8.

PMID:
24402036
43.

Retinal hyperaemia-related blood vessel artifacts are relevant to automated OCT layer segmentation.

Balk LJ, Mayer M, Uitdehaag BM, Petzold A.

J Neurol. 2014 Mar;261(3):511-7. doi: 10.1007/s00415-013-7226-2. Epub 2014 Jan 5.

PMID:
24390200
44.

Influence of the eye-tracking-based follow-up function in retinal nerve fiber layer thickness using fourier-domain optical coherence tomography.

Balk LJ, Petzold A.

Invest Ophthalmol Vis Sci. 2013 Apr 30;54(4):3045. doi: 10.1167/iovs.13-12073. No abstract available.

PMID:
23633680
45.

Positive association between dietary iron intake and iron status in HIV-infected children in Johannesburg, South Africa.

Kruger HS, Balk LJ, Viljoen M, Meyers TM.

Nutr Res. 2013 Jan;33(1):50-8. doi: 10.1016/j.nutres.2012.11.008. Epub 2012 Dec 20.

PMID:
23351410
46.

Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.

Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F.

Neurology. 2013 Jan 1;80(1):69-75. doi: 10.1212/WNL.0b013e31827b1a67. Epub 2012 Dec 12.

PMID:
23243070
47.

A simple sign for recognizing off-axis OCT measurement beam placement in the context of multicentre studies.

Balk LJ, de Vries-Knoppert WA, Petzold A.

PLoS One. 2012;7(11):e48222. doi: 10.1371/journal.pone.0048222. Epub 2012 Nov 8.

48.

Microcystic macular oedema confirmed, but not specific for multiple sclerosis.

Balk LJ, Killestein J, Polman CH, Uitdehaag BM, Petzold A.

Brain. 2012 Dec;135(Pt 12):e226; author reply e227. doi: 10.1093/brain/aws216. Epub 2012 Oct 17. No abstract available.

PMID:
23078994
49.

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J.

Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19.

PMID:
22992450
50.

The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomography.

Balk LJ, Sonder JM, Strijbis EM, Twisk JW, Killestein J, Uitdehaag BM, Polman CH, Petzold A.

Invest Ophthalmol Vis Sci. 2012 Mar 9;53(3):1251-7. doi: 10.1167/iovs.11-8209.

PMID:
22266522

Supplemental Content

Support Center